Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$81.43 USD
-1.89 (-2.27%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $81.45 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.43 USD
-1.89 (-2.27%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $81.45 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed
by Zacks Equity Research
Sucampo Pharmaceuticals, Inc. (SCMP) reported adjusted earnings of 68 cents per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 49 cents by 38.8%.
The Zacks Analyst Blog Highlights: Dow Chemical, Shell, HSBC Holdings, Exxon Mobil and Dr. Reddy's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Dow Chemical, Shell, HSBC Holdings, Exxon Mobil and Dr. Reddy's
Fewer Beats, But Q4 Growth is Highest in 2 Years
by Sheraz Mian
Today's Research Daily features a real-time scorecard of the Q4 earnings season, in addition to research reports on Shell (RDS.A) and others.
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen